RESUMO
This study sought to investigate the prevalence of colistin-resistant Gram-negative bacteria (CoR-GNB) amongPseudomonas aeruginosa, Acinetobacter baumannii, Escherichia coli, and Klebsiella pneumoniae isolated frompatients with bacteremia and to identify other antimicrobials as a potential therapy for CoR-GNB infections. Weretrospectively reviewed the data of non-repeated clinical bacterial isolates from patients admitted to PhramongkutklaoHospital during May 2017–April 2018. We obtained the minimum inhibitory concentrations (MICs) of the studiedisolates and interpreted the MIC values followed by the Clinical and Laboratory Standards Institute (CLSI) criteria. Outof 623 bacterial isolates, the prevalence of E. coli was predominantly high (349), followed by K. pneumoniae (150),P. aeruginosa (64), and A. baumannii (60). The CoR-GNB rates among E. coli, K. pneumoniae, A. baumannii, andP. aeruginosa were 2.9%, 17.3%, 5.0%, and 1.6%, respectively. Seven out of 26 colistin-resistant K. pneumoniaeisolates and seven out of 10 colistin-resistant E. coli isolates were still susceptible to carbapenems (the MICs forimipenem and meropenem were ≤1 µg/ml). Tigecycline and aminoglycosides might be the best therapeutic choicesagainst CoR-GNB. In conclusion, our findings confirmed a CoR-GNB prevalence of approximately 1.6%–17.3%,depending on the bacterial species. Certain available antimicrobials remain effective against CoR-GNB.